What is the difference between Cyclophosphamide Injection and Paclitaxel?

Cyclophosphamide Injection and Paclitaxel are both Chemotherapys, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Can Cyclophosphamide Injection and Paclitaxel be used for the same conditions?

Both medications are prescribed for overlapping indications including Hodgkin's disease and lymphocytic lymphoma (nodular or diffuse). Always verify with your prescriber and the current FDA label before switching.

Is Cyclophosphamide the same as Paclitaxel?

No. Cyclophosphamide (Cyclophosphamide Injection) and Paclitaxel (Paclitaxel) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, Cyclophosphamide Injection or Paclitaxel?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from Cyclophosphamide Injection to Paclitaxel?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

Cyclophosphamide Injection vs Paclitaxel

Compare Cyclophosphamide Injection (Cyclophosphamide) and Paclitaxel (Paclitaxel), clinical data, side effects, and patient experiences.

Cyclophosphamide Injection

Cyclophosphamide · Chemotherapy

How it works

12.1 Mechanism of Action The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cy...

Approved for

Hodgkin's disease

lymphocytic lymphoma (nodular or diffuse)

mixed-cell type lymphoma

histiocytic lymphoma

IntravenousTablet

Paclitaxel

Paclitaxel · Chemotherapy

How it works

Other agent

Approved for

INDICATIONS AND USAGE Paclitaxel Injection

USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy

Paclitaxel Injection

USP is indicated in combination with cisplatin. Paclitaxel Injection

IntravenousTablet

Quick Comparison

Cyclophosphamide InjectionPaclitaxel

Drug Class

Chemotherapy

Route

Intravenous

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Cyclophosphamide Injection

Drug Not Working

1-10%

Fever

1-10%

Nausea

1-10%

Diarrhea

0.1-1%

Vomiting

0.1-1%

Paclitaxel

Nausea

1-10%

Diarrhea

1-10%

Shortness of Breath

1-10%

Fatigue

1-10%

Fever

1-10%

Vomiting

1-10%

FDA Warnings

Cyclophosphamide Injection

5 WARNINGS AND PRECAUTIONS • Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections - Severe immunosuppression may lead to serious and sometimes fatal infections
2 ) • Cardiotoxicity - Myocarditis, myopericarditis, pericardial effusion, arrhythmias and congestive heart failure, which may be fatal, have been reported
Monitor patients, especially those with risk factors for cardio toxicity or pre-existing cardiac disease
5 ) • Veno-occlusive Liver Disease - Fatal outcome can occur

Paclitaxel

WARNING Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents
Fatal reactions have occurred in patients despite premedication

Clinical Trial Data

No head-to-head clinical studies found for Cyclophosphamide Injection vs Paclitaxel.

Cyclophosphamide Injection vs Paclitaxel: What You Should Know

Key Differences

Both Cyclophosphamide Injection and Paclitaxel belong to the Chemotherapy class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

Cyclophosphamide Injection carries 4 FDA warnings. Paclitaxel carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Cisplatin vs Paclitaxel→Cisplatin vs Cyclophosphamide Injection→Capecitabine vs Paclitaxel→Capecitabine vs Cyclophosphamide Injection→Etoposide vs Paclitaxel→Cyclophosphamide For Injection vs Paclitaxel→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

Cyclophosphamide Injection: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Paclitaxel: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

Cyclophosphamide Injection vs Paclitaxel

Compare Cyclophosphamide Injection (Cyclophosphamide) and Paclitaxel (Paclitaxel), clinical data, side effects, and patient experiences.

Cyclophosphamide Injection

Cyclophosphamide · Chemotherapy

How it works

12.1 Mechanism of Action The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cy...

Approved for

Hodgkin's disease

lymphocytic lymphoma (nodular or diffuse)

mixed-cell type lymphoma

histiocytic lymphoma

IntravenousTablet

Paclitaxel

Paclitaxel · Chemotherapy

How it works

Other agent

Approved for

INDICATIONS AND USAGE Paclitaxel Injection

USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy

Paclitaxel Injection

USP is indicated in combination with cisplatin. Paclitaxel Injection

IntravenousTablet

Quick Comparison

Cyclophosphamide InjectionPaclitaxel

Drug Class

Chemotherapy

Route

Intravenous

Half-Life

N/A

FDA Approved

N/A

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

Cyclophosphamide Injection

Drug Not Working

1-10%

Fever

1-10%

Nausea

1-10%

Diarrhea

0.1-1%

Vomiting

0.1-1%

Paclitaxel

Nausea

1-10%

Diarrhea

1-10%

Shortness of Breath

1-10%

Fatigue

1-10%

Fever

1-10%

Vomiting

1-10%

FDA Warnings

Cyclophosphamide Injection

5 WARNINGS AND PRECAUTIONS • Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections - Severe immunosuppression may lead to serious and sometimes fatal infections
2 ) • Cardiotoxicity - Myocarditis, myopericarditis, pericardial effusion, arrhythmias and congestive heart failure, which may be fatal, have been reported
Monitor patients, especially those with risk factors for cardio toxicity or pre-existing cardiac disease
5 ) • Veno-occlusive Liver Disease - Fatal outcome can occur

Paclitaxel

WARNING Paclitaxel should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents
Fatal reactions have occurred in patients despite premedication

Clinical Trial Data

No head-to-head clinical studies found for Cyclophosphamide Injection vs Paclitaxel.

Cyclophosphamide Injection vs Paclitaxel: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.